[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100617241":3},{"organization":4,"outcomesModule":7,"designInfo":30,"detailedDescription":33,"studyPopulation":34,"armGroups":29,"interventions":29,"overallOfficials":29,"centralContacts":35,"locations":41,"responsibleParty":58,"collaborators":29,"id":60,"slug":61,"hasResults":62,"nctId":63,"briefTitle":64,"officialTitle":65,"acronym":66,"eligibilityCriteria":67,"healthyVolunteers":62,"sex":68,"minAge":69,"maxAge":29,"enrollmentInfo":70,"targetDuration":29,"studyType":73,"phases":29,"briefSummary":74,"conditions":75,"keywords":77,"overallStatus":44,"whyStopped":29,"lastUpdateSubmitDate":79,"lastUpdatePostDateStruct":80,"startDateStruct":83,"completionDateStruct":85,"leadSponsor":87,"locationsCount":88},{"fullName":5,"class":6},"AstraZeneca","INDUSTRY",{"primaryOutcomes":8,"secondaryOutcomes":19,"otherOutcomes":29},[9,13,16],{"measure":10,"description":11,"timeFrame":12},"Treatment Patterns","Proportion of patients with different treatment regimens","Up to 50 months",{"measure":14,"description":15,"timeFrame":12},"Proportion of unresected patients in SI\u002FII\u002FIII","Proportion of patients who are unresected among SI\u002FII\u002FIII NSCLC patients enrolled, respectively",{"measure":17,"description":18,"timeFrame":12},"CRT rate in USIII","Proportion of patients who have CRT regimen among unresected SIII patients enrolled",[20,23,26],{"measure":21,"description":22,"timeFrame":12},"Treatment Duration","TKI treatment duration and discontinuation reason in EGFRm patients\n\n* Duration of treatment\n* Treatment discontinuation (time to discontinuation, and reason for discontinuation)",{"measure":24,"description":25,"timeFrame":12},"Patterns of recurrence","Type of recurrence following initial treatment regimen (Loco-regional recurrence, distant recurrence, other)",{"measure":27,"description":28,"timeFrame":12},"Guideline adoption rate","Resected EGFRm Stage IB-III\n\n* Proportion of patients received guideline recommended TKI adjuvant regimen among a. resected EGFRm Stage IB-III patients; b. patients with TKI adjuvant therapy Unresected Stage III\n* Proportion of patients received guideline recommended systemic IO and TKI regimens among patients who received CRT",null,{"allocation":29,"interventionModel":29,"interventionModelDescription":29,"primaryPurpose":29,"observationalModel":31,"timePerspective":32,"maskingInfo":29},"COHORT","RETROSPECTIVE","The primary objective of this study is to understand the evolution of initial treatment patterns among patients with early-stage (I-III) NSCLC.","The target population for this study will be patients diagnosed with stage I-III NSCLC treated in routine clinical practice with various treatment regimens (e.g., definitive treatment with surgery or radiotherapy, neoadjuvant, adjuvant and perioperative systemic therapies) who meet the study eligibility criteria.",[36],{"name":37,"role":38,"phone":39,"phoneExt":29,"email":40},"AstraZeneca Clinical Study Information Center","CONTACT","1-877-240-9479","information.center@astrazeneca.com",[42],{"facility":43,"status":44,"city":45,"state":29,"zip":29,"country":46,"countryCode":47,"cosmosGeoPoint":48,"geoPoint":53,"contacts":54},"Research Site","RECRUITING","Beijing","China","CN",{"type":49,"coordinates":50},"Point",[51,52],116.39723,39.9075,{"lat":52,"lon":51},[55],{"name":56,"role":38,"phone":29,"phoneExt":29,"email":57},"Shugeng Gao","gaoshugeng@cicams.ac.cn",{"type":59,"investigatorFullName":29,"investigatorTitle":29,"investigatorAffiliation":29,"oldNameTitle":29,"oldOrganization":29},"SPONSOR","100617241","a-multi-centre-chart-review-study-of-stage-i-iii-non-small-cell-lung-cancer-in-china-100617241",false,"NCT07316062","A Multi-centre Chart Review Study of Stage I-III Non-Small Cell Lung Cancer in China","A Multi-centre Chart Review Study on the Treatment Patterns and Outcomes of Stage I-III Non-Small Cell Lung Cancer in China","MAP","Inclusion Criteria:\n\n* Stage I-III at initial NSCLC diagnosis\n* Aged ≥18 years at first diagnosis of NSCLC\n* Timeframe of NSCLC diagnosis:\n\nFor DE1: diagnosed with NSCLC during the period between May 1st 2025 and December 31st 2025 For DE2: diagnosed with NSCLC during the period between May 1st 2026 and December 31st 2026 For DE3: diagnosed with NSCLC during the period between May 1st 2027 and December 31st 2027\n\nExclusion Criteria:\n\n* NSCLC is not the primary cancer diagnosis\n* Patients with a recent history of other tumor or concurrent other tumor\n* Patients participating in interventional clinical trials at time of initial diagnosis\n* Patients with positive pregnancy status at the time of diagnosis","ALL","18 Years",{"count":71,"type":72},3000,"ESTIMATED","OBSERVATIONAL","This chart review study is proposed in China to understand the treatment patterns, biomarker testing, and clinical outcomes with SOC and some selected regimens among patients diagnosed with stage I-III NSCLC.",[76],"Non-Small-Cell Lung",[78],"NSCLC, chart review","2026-09-10",{"date":81,"type":82},"2026-09-11","ACTUAL",{"date":84,"type":82},"2026-04-29",{"date":86,"type":72},"2029-04-30",{"name":5,"class":6},1]